1033225-45-4

Basic information

• Product Name: 1-(2,6-difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide
• Synonyms: 1-(2,6-difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide
• CAS NO: 1033225-45-4
• Molecular Weight: 282.271
• Mol File: 1033225-45-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(2,6-difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,6-difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide(1033225-45-4)
• EPA Substance Registry System: 1-(2,6-difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide(1033225-45-4)

Safety Data

• Hazardous Substances Data: 1033225-45-4(Hazardous Substances Data)

Upstream product

• 1033225-44-3 N-(2,6-difluorophenyl)benzene-1,2-diamine 
• 1033225-43-2 2,6-difluoro-N-(2-nitrophenyl)aniline 
• 1233485-18-1 1-(tert-butyloxycarbonyl)-3-(2,6-difluorophenyl)-1,3-dihydrobenzothiadiazole-S,S-dioxide 
• 1233485-16-9 tert-butyl 2-(2,6-difluorophenylamino)phenylcarbamate 
• 5509-65-9 2,6-difluoroaniline 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 1033225-46-5 1-(3-bromopropyl)-3-(2,6-difluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033227-56-3 C₁₆H₁₄F₂N₂O₃S 
• 1033221-94-1 1-(2,6-difluorophenyl)-1,3-dihydro-3-[2-(1-piperazinyl)ethyl]benzothiadiazole-S,S-dioxide 
• 1233485-20-5 1-(2,6-difluorophenyl)-1,3-dihydro-3-[2-(1-piperazinyl)ethyl]benzothiadiazole-S,S-dioxide succinate 

Relevant articles and documents

Development of a pilot-plant-scale synthesis of an alkylated dihydrobenzothiadiazole S, S-dioxide: Incorporation of a late-stage mitsunobu reaction

The process used to prepare a functionalized dihydrobenzothiadiazole S,S-dioxide on a pilot plant scale is described. Key changes to the original synthesis included: modifying SNAr reaction conditions between a substituted aniline and 2-fluoron

ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.